## PROSTATE CANCER BIOMARKERS SIMPLIFIED

### COMMERCIAL MARKERS

<table>
<thead>
<tr>
<th></th>
<th>Prolaris*&lt;sup&gt;1-16&lt;/sup&gt;</th>
<th>OncotypeDx*&lt;sup&gt;11,17-22&lt;/sup&gt;</th>
<th>Decipher Bx*&lt;sup&gt;11,23-30&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active Surveillance Recommendations (DSM Risk) Repeatedly Proven in Untreated Patients</td>
<td>✓</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Multi-Modal Recommendations (Mets Risk) Repeatedly Proven in Treated Patients</td>
<td>✓</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Studied in ALL NCCN Risk Categories</td>
<td>✓</td>
<td>x</td>
<td>✓</td>
</tr>
<tr>
<td>Covered by Medicare for ALL NCCN Risk Categories</td>
<td>✓</td>
<td>x</td>
<td>✓</td>
</tr>
<tr>
<td>Includes Clinical and Pathological Features</td>
<td>✓</td>
<td>✓</td>
<td>x</td>
</tr>
<tr>
<td>More Prognostic than Actual Adverse Pathology</td>
<td>✓</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Proven to Impact Treatment Decisions</td>
<td>✓</td>
<td>✓</td>
<td>x</td>
</tr>
</tbody>
</table>

### Why Prolaris? Because Every Man Deserves a Better Answer.

Above data collected on 2/1/21
REFERENCES:

1. NCCN® Clinical Practice Guidelines in Oncology – Prostate Cancer (V.1.2021. MS-65)
16. Canter, C et al. Biopsy-derived cell cycle progression score outperformed pathological upgrading or upstaging in predicting biochemical recurrence after surgery. Poster session presented at: Western AUA; 2018 October 28; Maui, HI

† Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN® Guidelines) for Prostate Cancer V.1.2021. ©2021 National Comprehensive Cancer Network, Inc. 2019. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN content are trademarks owned by the National Comprehensive Cancer Network, Inc.